Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: Toxicity and immunological effects

Clinical Cancer Research

Volumn 9, Issue 4, 2003, Pages 1354-1360

  Hutson, Thomas E ^a   Molto, Luis ^b   Mekhail, Tarek ^a   Elson, Paul ^a   Finke, James ^a,b   Tannenbaum, Charles ^a,b   Borden, Ernest ^a   Dreicer, Robert ^a   Olencki, Thomas ^a   Bukowski, Ronald M ^a,b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; CONSENSUS INTERFERON; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MIG CHEMOKINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FATIGUE; FEMALE; GENE EXPRESSION; HUMAN; KIDNEY CARCINOMA; MALE; METASTASIS; MONONUCLEAR CELL; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; BLOTTING, SOUTHERN; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INTERFERON TYPE I, RECOMBINANT; INTERFERON TYPE II; KIDNEY NEOPLASMS; LEUKOCYTES, MONONUCLEAR; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER;

EID: 0037386823     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Motzer, R. J., and Russo, P. Systemic therapy for renal cell carcinoma. J. Urol., 163: 408-417, 2000.
2. Yagoda, A., Abi-Rached, B., and Petrylak, D. Chemotherapy for advanced renal cell carcinoma: 1983-1993. Semin. Oncol., 22: 42-48, 1995.
3. Bukowski, R. M. Natural history and therapy of metastatic renal cell carcinoma: role of interleukin-2. Cancer (Phila.), 80: 1198-1220, 1997.
4. Negrier, S., Escudier, B., Lasset, C., Savary, J., Douillard, J. Y., Chevreau, C., Ravaud, A., Mercatello, A., Penry, J., Mousseau, M., Philip, T., and Tursz, T. Recombinant human Interleukin 2, recombinant human interferon α-2a, or both in metastatic renal cell carcinoma. N. Eng. J. Med., 338: 1272-1278, 1998.
5. Lee, D. S., White, D. E., Hurst, R., Rosenberg, S. A., and Yang, J. C. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2 based immunotherapy. Cancer J. Sci. Am., 4: 86-93, 1998.
6. Flanigan, R. C., and Yonover, P. M. The role of resection for patients with renal carcinoma. Curr. Oncol. Rep., 3: 424-432, 2001.
7. Ozes, O. N., Reiter, Z., Klein, S., Blatt, L., and Taylor, M. W. A comparison of interferon-conl with natural recombinant interferon-α: antiviral, antiproliferative and natural killer inducing activities. J. Interferon Res., 12: 55-59, 1992.
8. Altrock, B. W., Fagin, K. D., Hockman, H. R., Fish, E. N., Goldstein, L., Chang, D., Druker, K., and Stebbing, N. Antiviral and antitumor effects of a human interferon analog, IFNaCon1, assessed in hamsters. J. Interferon. Res., 6: 405-415, 1986.
9. Blatt, L. M., Davis, J. M., Klein, S. B., and Taylor, M. W. The biologic activity and molecular characterization of a novel synthetic interferon-α, consensus interferon. J. Interferon Cytokine Res., 16: 489-499, 1996.
10. Fish, E. N., Bannerjee, K., and Stebbing, N. Antiherpetic effects of a human α interferon analog, IFN-a con1 in hamsters. Antimicrob. Agents Chemother., 30: 52-56, 1986.
11. Fish, E. N., Bannerjee, K., and Stebbing, N. Effects of consensus interferon α against HSV-2 infection. Antiviral Res., 1 (Suppl.): 191-197, 1985.
12. Balkwill, F. R., Goldstein, L., and Stebbing, N. Differential actions of six human interferons against two human carcinomas growing in nude mice. Int. J. Cancer, 35: 613-617, 1985.
13. Yao, G. B., Fu, X. X., Tian, G. S., Xu, D. Z., Hao, L. J., Huangfu, Y. S., and Su, C. X. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with α-2a-interferon in Chinese patients with chronic hepatitis C virus infection. J. Gastroenterol. Hepatol., 15: 1165-1170, 2000.
14. Farber, J. M. A macrophage mRNA selectively induced by γ-interferon encodes a member of the platelet factor 4 family of cytokines. Proc. Natl. Acad. Sci. USA, 87: 5238, 1990.
15. Liao, F., Rabin, R. L., Yanelli, J. R., Konvares. L. G., Vanguri, P., and Farber, J. M. Human Mig chemokine: biochemical and functional characterization. J. Exp. Med., 182: 1301-1310, 1995.
16. Luster, A. D., Unkeless, J. C., and Ravetch, J. V. γ-interferon transcriptionally regulates an early response gene containing homology to platelet proteins. Nature (Lond.), 315: 672-676, 1985.
17. Farber, J. M. Mig and IP-10: CXC chemokines that target lymphocytes. J. Leukocyte Biol., 61: 246-252, 1997.
18. Loetscher, M. L., Gerber, B., Loetscher, P., Jones, S. A., Piali, L., Clark-Lewis, I., Baggiolini, M., and Moser, B. Chemokine receptor specific for IP-10 and Mig: structure, function and expression in activated T-lymphocytes. J. Exp. Med., 184: 963-970, 1996.
19. Luster, A. D., Greenberg, S. M., and Leder, P. The IP-10 chemokine binds to a specific cell surface heparin sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J. Exp. Med., 182: 219-226, 1995.
20. Angiolillo, A. L., Sgardari, C., Taub, D. D., Liao, F., Farber, J. M., Maheshwari, S., Kleinman, H. K., Reaman, G. H., and Tosato, G. Human interferon inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med., 182: 155, 1995.
21. Sgadari, C., Angiolillo, A. L., and Tosato, G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood, 87: 3877, 1996.
22. Uzzo, R. G., Rayman, P., Kolenko, V., Clark, P. E., Bloom, T., Ward, A. M., Molto, L., Tannenbaum, C., Wolford, L. J., Bukowski, R., Tubbs, R., and His, E. D. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin. Cancer Res., 5: 1219-1229, 1999.
23. Tong, M. J., Reddy, K. R., Lee, W. M., Pockros, P. J., Hoefs, J. C., Keeffe, E. B., Hollinger, F. B., Hathcote, E. J., White, H., Forest, R. T., Jesen, D. M., Krauitt, E. L., Fromm, H., Black, M., Blatt, L. M., Klein, M., and Lubiva, J. Treatment of chronic hepatitis C with consensus interferon: a multicentre, randomized controlled trial. Hepatology, 26: 747-754, 1997.
24. Heathcote, E. J., James, S., Mullen, K., Hauser, S. C., Rosenblate, H., Albert, D. G., and the Consensus Interferon Study Group. Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. Hepatology, 30: 562-566, 1999.
25. Heathcote, J. Consensus interferon: a novel interferon for the treatment of hepatitis C. J. Viral Hepatitis, 5 (Suppl. 1): 13-18, 1998.
26. Mekhail, T., Wood, L., and Bukowski, R. Interleukin-2 in cancer therapy - uses and optimum management of adverse effects. BioDrugs, 14: 299-318, 2000.
27. Tong, H. L., and Custer, J. G. Chemokine up-regulation and activated T-cell attraction by maturing dendritic cells. Science (Wash. DC), 284: 819-822, 1999.
28. Hutson, T. E., Mekhail, T., Molto, L., Tannenbaum, C., Finke, J., Olencki, T., Reiff-Buford, K., and Bukowski, R. M. Phase I trial of subcutaneously administered rHuIL-12 and rHuIFN-a2b in patients with metastatic renal cell carcinoma or malignant melanoma. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 20: 258, 2001.
29. Bukowski, R. M., Rayman, P., Molto, L., Tannenbaum, C. S., Olencki, T., Peereboom, D., Tubbs, R., McClain, D., Budd, G. T., Grffin, T., Novick, A., Hamilton, T. A., and Finke, J. Interferon-γ and CXC chemokine induction by interleukin 12 in renal cell carcinoma. Clin. Cancer Res., 5: 2780-2789, 1999.
30. Tannenbaum, C. S., Wicker, N., Armstrong, D., Tubbs, R., Finke, J., Bukowski, R. M., and Hamilton, T. A. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J. Immunol., 156: 693-698, 1996.
31. Tannenbaum, C. S., Tubbs, R., Armstrong, D., Finke, J. H., Bukowski, R. M., and Hamilton, T. A. The CXC chemokines IP-10 and Mig are necessary for IL-12 mediated regression of the mouse RENCA tumor. J. Immunol., 161: 927, 1998.
32. Matikainen, S., Paananen, A., Miettinen, M., Kurimoto, M., Timonen, T., Julkunen, I., and Sareneva, T. IFN-α and IL-18 synergistically enhance IFN-γ production in human NK cells: differential regulation of Stat4 activation and IFN-γ gene expression by IFN-α and IL-12. Eur. J. Immunol., 31: 2236-2245, 2001.
33. Byrnes, A. A., Ma, X., Cuomo, P., Park, K., Wahl, L., Wolf, S. F., Zhou, H., Trinchieri, G., and Karp, C. L. Type I interferons and IL-12: convergence and cross-regulation among mediators of cellular immunity. Eur. J. Immunol., 31: 2026-2034, 2001.